Introducing The Rowboat
Quite Possibly The Holy Grail of Investing.
Step 1: Sell the Put
( This is a Cash Covered Put, I have to have enough Cash to buy 100 shares per
contract if the option is exercised, this is also my maximum risk.)
CLSN @ $7.00
Sell To Open CLSN Feb 2013 $2 Put @ Market
Currently .30c bid /.35c time
15% return in 26 days
How to do this trade and commentary Video:
(Sign up for Auto-trading and have this trade done for you automatically)
http://youtu.be/tMFFWnJxmfI

Remember, no more than 5 or 10% of your portfolio should ever go into any one trade or position.

Step 2: IFit got Put to us, Now we “Lock-in” a profit.
Sell theCovered Call
(Do not buy this stock just to sell the covered Call)
Nothing was “Put” to us this month.
News:
Remember, no more than 5 or 10% of your portfolio should ever go
into any one trade or position.

How did we do last Month? /

CLSN @ $7.00

Move to Closed Positions

Strategy: Sell Puts

10% return in 26 days

1/19/2013 called away

12/24/2012 Sell To Open CLSN Jan13 2 Put $0.20

Cost basis $2.00 per share. Premiums collected: $.20c per share 10% Return in 1 month

$10,000 would have generated $1000.00

VHC @ $32.05

VirnetX Holding Corp (VHC)

Move to Closed Positions

5% return in 2 Months

History:

01/20/2013 Expired

11/19/2012 Sell To Open VHC Jan13 20 Put $1.00

Cost basis $20.00 per share. Premiums collected: $1.00 per share 5% Return in 2 month

$10,000 would have generated $500.00

current/Older Positions/History

This includes a running total for each open position.

CLWR @ $3.17

sell to open CLWR March13 $3 call @ Market

Currently

20c bid / 23c time

news:

http://www.bloomberg.com/news/2013-01-17/clearwire-investor-taran-seeks-higher-bid.html?

This could possibly go to $3.30

How to do this trade and commentary Video:

(Sign up for Auto-trading and have this trade done for you automatically)

http://youtu.be/l1MxbRGkHLM

History:

Cost basis $3.00 per share. Premiums collected: .85c per share 28.33% Return in 16 months

$10,000 would have generated $2833.00

actual trades:

01/19/2013 CLWR Jan13 5 Call expired
06/18/2012 Sell To Open CLWR Jan13 5 Call $0.05
09/19/2011 Sell To Open CLWR Jan12 4 Call $0.30
09/16/2011 Buy To Close CLWR Sep11 3 Put
09/16/2011 Buy CLWR – Option Assignment $3.00
08/23/2011 Sell To Open CLWR Sep11 3 Put $0.50

Clearwire Corporation, through its subsidiaries, provides fourth generation wireless broadband services in the United States. The company builds and operates mobile broadband networks that offer high-speed mobile Internet and residential Internet access services. It serves retail customers through its CLEAR brand. The company markets its products and services directly to consumers, as well as through cellular retailers, consumer electronics stores, satellite television dealers, and computer sales and repair stores; and through company-operated retail outlets. As of December 31, 2011, it had approximately 1.3 million retail and 9.1 million wholesale subscribers. The company is headquartered in Bellevue, Washington. Clearwire Corporation is a subsidiary of Sprint HoldCo LLC

News:

http://finance.yahoo.com/news/sprints-seals-deal-clearwire-171948629.html

DMND @ $13.99

Put to us @ $32.00

Hold

No good options at this time

3.59% Return

History:

Cost basis $32.00 per share. Premiums collected: 1.15 per share 3.59% Return in 11 months

$10,000 would have generated $359.00

actual trades:

09/24/2012 Sell To Open DMND Dec12 30 Call $0.20 03/20/2012 Sell To Open DMND Jun12 33 Call $0.25 03/18/2012 Buy To Close EXPIRED DMND Mar12 32 CALL 02/21/2012 Sell To Open DMND Mar12 32 Call $0.20 02/17/2012 Buy DMND – Option Assignment $32.00 02/17/2012 Buy To Close DMND Feb12 32 Put 02/06/2012 Sell To Open DMND Feb12 32 Put $1.50

Diamond Foods, Inc. engages in processing, marketing, and distributing snack products. It provides snack products, including roasted, glazed and flavored nuts, trail mixes, dried fruit, seeds, microwave popcorn products, and potato and tortilla chips under the Emerald, Pop Secret, and Kettle brands. The company also offers culinary, in-shell, and ingredient nuts under the Diamond of California brand name. It markets its culinary nuts to individuals who prepare meals or baked goods at home; and ingredient nuts to food processors, restaurants, bakeries, and food service companies and their suppliers. The company sells its products directly to national grocery, mass merchandiser, clubs, convenience stores, and drug store chains in the United States, the United Kingdom, Germany, the Netherlands, Spain, Canada, South Korea, Turkey, China, and Japan. Diamond Foods, Inc. was founded in 1912 and is based in San Francisco, California.

Diamond Foods, Inc.

600 Montgomery Street 13th Floor

San Francisco, CA 94111-2702 Phone: 415-445-7444

Website: http://www.diamondfoods.com

News:http://seekingalpha.com/article/1013151-diamond-s-restatement-opens-the-door-to-many-options-including-a-buyout?

ELN @ $10.00

Sell To Open ELN April13 $12 Call @ Market

Currently

10c bid / 15c time

News:

History:

Cost basis $12.00 per share. Premiums collected: $1.75 per share 14.58% Return in 6 months

$10,000 would have generated $1458.00

actual trades:

10/22/2012 Sell To Open ELN Jan13 14 Call $0.10

08/20/2012 Sell To Open ELN Oct12 13 Call $0.35

07/23/2012 Sell To Open ELN Aug12 12 Put $1.20

Elan shareholders on the register on December 14, 2012, the record date, received 1 Prothena ordinary share for every 41 Elan ordinary shares or ADSs held.

Elan Corporation, plc operates as a neuroscience-based biotechnology company in the United States, Ireland, and internationally. It engages in research, development, and commercial activities primarily in the areas of Alzheimer s disease, Parkinson s disease, and multiple sclerosis (MS). The company offers Tysabri, an alpha -4 integrin inhibitor primarily for the treatment of MS. It is also developing ELND005, a beta amyloid anti- aggregation agent to treat Alzheimer s disease, which completed Phase II clinical trial. In addition, the company focuses on the discovery and development of antibodies to neo-epitope related targets for the treatment of a range of indications, including amyloidosis, diabetes, cancer, and macular degeneration; and drugs for oncology related diseases comprising NEOD001 for the treatment of AL amyloidosis, as well as focuses on developing ELND005 for bipolar disorder. Further, the company, through collaboration agreement with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohn s disease. Additionally, Elan Corporation, plc, through a 49.9% interest in Janssen AI, develops beta amyloid immunotherapies, including bapineuzumab, ACC-001, and other compounds to treat Alzheimer s disease.

The company also has collaboration agreements with Cambridge-Elan Centre, Dublin Neurological Institute, University College Dublin, and Proteostasis. Elan Corporation, plc was founded in 1969 and is headquartered in Dublin, Ireland.

Elan Corporation, plc

Treasury Building

Lower Grand Canal Street

Dublin, 2

Ireland

Phone: 353 1 709 4000

Fax: 353 1 709 4700

Website: http://www.elan.com

news

http://finance.yahoo.com/news/elan-announces-availability-information-statement-213000320.html

FMCN @ $25.30

Focus Media Holding Ltd

Sell To Open FMCN April13 $26 Call @ Market

Currently

55c bid / 63c time

Current bid on the buy out is $27.50

History:

Cost basis $ 24.00 per share.

Premiums collected: $ 2.10 per share 8.75 % Return in 10 months

$10,000 would have generated $875.00

10/22/2012 Sell To Open FMCN Jan13 27 Call $0.20
08/14/2012 Buy To Close FMCN Oct12 27 Call -$0.50
07/23/2012 Sell To Open FMCN Oct12 27 Call $0.40
05/21/2012 Sell To Open FMCN Jul12 27 Call$0.40
04/23/2012 Sell To Open FMCN May12 27 Call $0.45
04/20/2012 Buy FMCN – Option Assignment$24.00
04/20/2012 Buy To Close FMCN Apr12 24 Put
03/19/2012 Sell To Open FMCN Apr12 24 Put $1.15

Focus Media Holding Limited, a multi-platform digital media company, operates liquid crystal display (LCD) network using audiovisual digital displays in China. The company engages in selling out-of-home advertising time slots on its network of flat-panel digital advertising displays located in high traffic areas of commercial, residential, and public buildings, such as malls, hotels, and the lobbies of apartment buildings, as well as in-store network. It provides advertising services on poster frames, on screens in movie theatres, and on traditional outdoor billboards. As of December 31, 2011, the company had a LCD display network of approximately 155,751 flat-panel digital displays in approximately 114 cities; in-store network of approximately 50,076 LCD displays in approximately 1,576 hypermarkets, 217 supermarkets, and 1,008 convenience stores; poster frame network of approximately 445,126 non-digital frames and LCD 1.0 picture frame devices, as well as leased screen time in approximately 316 movie theaters, including 2,190 screens. Focus Media Holding Limited is headquartered in Central, Hong Kong.

News:


http://www.reuters.com/article/2013/01/14/china-accounting-idUSL2N0AJ24120130114?type=companyNews&feedType=RS S&feedName=companyNews&rpc=43

ISIS @ $14.36

Isis Pharmaceuticals, Inc. (ISIS)

Called away, move to closed positions

10% Return in 2 months

History:

Cost basis $13.00 per share. Premiums collected: $1.30 per share 10% Return in 2 months

$10,000 would have generated $1,000.00

actual trades:

01/19/13 Called away

10/22/2012 Sell To Open ISIS Jan13 13 Call $0.10 09/24/2012 Sell To Open ISIS Oct12 13 Put $1.20

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using antisense drug discovery platform. Its product pipeline comprises 26 drugs to primarily treat cardiovascular, metabolic, severe, and rare diseases, as well as cancer. The company s flagship product, KYNAMRO, is an apo-B synthesis inhibitor in development for the reduction of low-density lipoprotein cholesterol. The company has collaboration agreements with Biogen Idec to develop and commercialize ISIS -SMNRx for the treatment of spinal muscular atrophy; Bristol-Myers Squibb to discover, develop, and commercialize antisense drugs targeting proprotein convertase subtilisin/kexin type 9; and Ortho-McNeil-Janssen Pharmaceuticals, Inc. to discover, develop, and commercialize antisense drugs to treat metabolic diseases, including type 2 diabetes. It also has a strategic relationship with Eli Lilly and Company for the development of LY2181308, an antisense inhibitor of survivin; and a strategic alliance with GlaxoSmithKline to develop new drugs against targets for rare and serious diseases. The company was founded in 1989 and is headquartered in Carlsbad, California.

Isis Pharmaceuticals, Inc.

2855 Gazelle Court

Carlsbad, CA 92010

Phone: 760-931-9200 Fax: 760-603-2700

Website: http://www.isispharm.com

News:

http://www.fool.com/investing/general/2012/12/20/3-things-to-watch-at-isis-pharmaceuticals.aspx

ONTY @ $2.19

HOLD

there are no good options at this time.

History:

Cost basis $5.00 per share. Premiums collected: 2.15 per share 43% Return in 12 months

$10,000 would have generated $4300.00

actual trades:

11/19/2012 Sell To Open ONTY Jan13 6 Call $0.55
05/21/2012 Sell To Open ONTY Nov12 7 Call $0.05
03/20/2012 Sell To Open ONTY May12 6 Call $0.05
03/16/2012 Buy ONTY – Option Assignment $5.00
03/16/2012 Buy To Close ONTY Mar12 $5 Put
02/21/2012 Sell To Open ONTY Mar12 $5 Put $0.70
02/19/2012 Buy To Close EXPIRED ONTY FEB12 $5 PUT
01/30/2012 Sell To Open ONTY Feb12 5 Put $0.50
01/22/2012 Buy To Close EXPIRED ONTY JAN12 $5 PUT
01/09/2012 Sell To Open ONTY Jan12 5 Put $0.30

Oncothyreon Inc.(ONTY), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. The company also develops PX-866, a small molecule that is in Phase II trials. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine. The company operates in Canada, the United States, Barbados, and Europe. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Oncothyreon Inc

2601 Fourth Avenue Suite 500

Seattle, WA 98121 Phone: 206-801-2100 Fax: 206-801-2101

Website: http://www.oncothyreon.com

News:

Large Institutions and insiders are buying, not selling.

PAAS @ $18.42

Hold

there are no good options at this time.

History:

Cost basis $36.00 per share.

Premiums collected: $3.50 per share

Dividends : .07c

Total: $3.52

9.77% Return in 20 months

$10,000 would have generated $977.00

actual trades:

09/24/2012 Sell To Open PAAS Jan13 40 Call $0.05 01/30/2012Sell To Open PAAS Jul12 36 Call $0.20 12/06/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025

10/24/2011 Sell To Open PAAS Jan12 36 Call $0.40
10/22/2011 Buy To Close EXPIRED PAAS Oct11 36 Call
09/08/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025
06/20/2011 Sell To Open PAAS Oct11 36 Call $0.80
06/19/2011 Buy To Close EXPIRED PAAS JUN11 36 CALL
06/16/2011 PAAS QUALIFIED DIVIDEND $.025
05/23/2011 Sell To Open PAAS Jun11 36 Call $0.50
05/20/2011 Buy PAAS – Option Assignment $36.00
05/20/2011 Buy To Close PAAS May11 36 Put $0.00
04/18/2011 Sell To Open PAAS May11 36 Put $1.55

Pan American Silver Corp. engages in the exploration, development, extraction, processing, production, refining, reclamation, and operation of silver properties. The company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Pan American Silver Corp.

625 Howe Street Suite 1500

Vancouver, BC V6C 2T6 Phone: 604-684-1175 Fax: 604-684-0147

Website: http://www.panamericansilver.com

News:

http://finance.yahoo.com/news/final-glance-silver-companies-230957452.html

PAY @ $32.44

Sell To Open PAY July13 43 Call @ market

Currently

45c bid / 58c time

History:

Cost basis $43.00 per share. Premiums collected: $3.36 per share 7.63% Return in 19 months

$10,000 would have generated $758.00

actual trades:

10/22/2012 Sell To Open PAY Jan13 44 Call $0.10

06/18/2012 Sell To Open PAY Oct12 $44 Call $0.35

05/21/2012 Sell To Open PAY Jun12 50 Call $1.00

04/16/2012 Sell To Open PAY May12 57.5 Call $1.02

04/16/2012 Buy To Close PAY Apr12 49 Call -$5.36

01/23/2012 Sell To Open PAY Apr12 49 Call $0.40

01/22/2012 Buy To Close EXPIRED PAY JAN12 49 CALL

10/31/2011 Sell To Open PAY Jan12 49 Call $0.90

10/31/2011 Buy To Close PAY Jan12 46 Call -$1.90

10/24/2011 Sell To Open PAY Jan12 46 Call $1.10

10/22/2011 Buy To Close EXPIRED PAY Oct11 42 Call

08/23/2011 Sell To Open PAY Oct11 42 Call $0.60

08/21/2011 Buy To Close EXPIRED PAY AUG11 46

CALL

07/19/2011 Sell To Open PAY Aug11 46 Call $1.05

07/17/2011 Buy To Close EXPIRED PAY JUL11 44 CALL

06/20/2011 Sell To Open PAY Jul11 44 Call $0.75

06/17/2011 Buy To Close PAY Jun11 43 Put $0.00

06/17/2011 Buy PAY – Option Assignment $43.00

05/23/2011 Sell To Open PAY Jun11 43 Put $1.70

VeriFone Systems, Inc. designs, markets, and services electronic payment solutions that enable secure electronic payments among consumers, merchants, and financial institutions worldwide. The company provides countertop electronic payment systems that accept magnetic, smart card, and contactless/radio frequency identification cards; and support credit, debit, check, electronic benefits transfer, and various pre-paid products, as well as offers wireless system solutions. The company also provides products for the point of sale applications, which include displays, user-friendly interfaces, electronic cash registers (ECR) interfaces, durable key pads, and signature capture functionality; and contactless/near field communication (NFC) payment solutions for consumer-activated transactions using contactless cards, tokens, or NFC enabled mobile phones. In addition, it offers various products for petroleum companies, such as integrated electronic payment systems that combine card processing, fuel dispensing, and ECR functions, as well as secure payment systems for integration with petroleum pump controllers and systems. Further, the company provides server-based transaction products; secure payment hardware and software integration modules; and VeriShield Protect, a solution that encrypts and protects consumer card data. Additionally, it offers client services, including payment system consulting, deployment, on-site and telephone-based installation and training, help desk support, repairs, replacement of impaired system solutions, asset tracking, and reporting; and project management services. The company serves financial institutions, payment processors, petroleum companies, retailers, government organizations, and healthcare companies, as well as independent.

sales organizations. The company was formerly known as VeriFone Holdings, Inc. and

changed its name to VeriFone Systems, Inc. in May 2010. The company is headquartered in San Jose, California.

VeriFone Systems, Inc

2099 Gateway Place Suite 600

San Jose, CA 95110

Phone: 408-232-7800 Fax: 408-232-7811

Website: http://www.verifone.com

News:

http://beta.fool.com/techjunk13/2012/12/19/beaten-down-stock-deserves-be-your-radar/19368/?ticker=PAY&source=eogyholnk0000001

QCOR @ $25.53

Questcor Pharmaceuticals, Inc. (QCOR)

Sell To Open QCOR April13 $35 Call @ Market

Currently

55c bid / 63c time

History:

Cost basis $35.00 per share. Premiums collected: $1.25 per share 3.57% Return in 5 months

$10,000 would have generated $357.00

actual trades:

11/19/2012 Sell To Open QCOR Jan13 35 Call $0.15 10/22/2012 Sell To Open QCOR Nov12 38 Call $0.15 09/24/2012 Sell To Open QCOR Oct12 44 Call $0.05 08/20/2012 Sell To Open QCOR Sep12 35 Put $0.90

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Acthar Gel, an injectable drug for the treatment of acute exacerbations of multiple sclerosis in adults; to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company s H.P. Acthar Gel also focuses on rheumatology-related conditions, including collagen diseases and rheumatic disorders. In addition, it offers Doral for the treatment of insomnia. The company sells its Acthar primarily to specialty pharmacies; and Doral to pharmaceutical wholesalers. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California.

Questcor Pharmaceuticals, Inc.

1300 North Kellogg Drive Suite D

Anaheim, CA 92807

Phone: 714-786-4200 Fax: 714-789-4229

Website: http://www.questcor.com

News:

TPX @ $34.99

Tempur-Pedic International Inc.

HOLD

Feb13 $40 Call still cooking

History:

Cost basis $40.00 per share. Premiums collected: $1.50 per share 3.75% Return in 8 months

$10,000 would have generated $300.00

actual trades:

12/24/2012 Sell To OpenTPX Feb13 $40 Call $0.30

09/24/2012 Sell To Open TPX Dec12 43 Call $0.20

06/18/2012 Sell To Open TPX Sep12 41 Call $0.05

06/16/2012 Buy TPX – Option Assignment $40.00

05/21/2012 Sell To Open TPX Jun12 40 Put $0.95

Tempur-Pedic International Inc. engages in the manufacture, marketing, and distribution of bedding products in North America and internationally. It offers mattresses, pillows, and adjustable bed bases, as well as various cushions and other comfort products. The company sells its products under the TEMPUR and Tempur-Pedic brand names through furniture and bedding retailers, and non-spring and department stores; direct response program, Internet, and company-owned stores; hospitals, nursing homes, healthcare professionals, and medical retailers; and third party distributors. Tempur-Pedic International Inc. was founded in 1989 and is headquartered in Lexington, Kentucky.

Tempur Pedic International Inc.

1713 Jaggie Fox Way

Lexington, KY 40511

Phone: 800-878-8889 Fax: 859-514-4422

Website: http://www.tempurpedic.com

News:

Next Earnings is January 24th

TRGT @ $4.59

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $12.50 per share.

Premiums collected: $2.25 per share 18% Return in 15 months

$10,000 would have generated $1800.00

actual trades:

02/21/2012 Sell To Open TRGT May12 15 Call $0.25

11/28/2011 Sell To Open TRGT Feb12 15 Call $0.40

11/18/2011 Buy To Close TRGT Nov11 12.5 Put

11/18/2011 Buy TRGT – Option Assignment $12.50 10/23/2011 Sell to Open TRGT Nov 11 $12.50 PUT $1.60

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. Its lead program, TC-5214, a nicotinic channel modulator, is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder (MDD) and in Phase 2b clinical trial for switch monotherapy in patients with MDD. The company s novel small molecule product candidates under Phase 2 clinical development include TC-5619 for treating negative symptoms and cognitive dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and Alzheimer s disease; AZD3480 as a treatment for mild to moderate Alzheimer s disease; AZD1446 as a treatment for Alzheimer s disease; and TC-6987 for the treatment of inflammatory disorders, including.

asthma and Type 2 diabetes. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

Targacept, Inc.

200 East First Street Suite 300

Winston-Salem, NC 27101-4165 Phone: 336-480-2100

Fax: 336-480-2107

Website: http://www.targacept.com

News:

next earnings is Feb 18th

VHC @ $32.05

VirnetX Holding Corp (VHC)

Move to Closed Positions

5% return in 2 Months

History:

01/20/2013 Expired

11/19/2012 Sell To Open VHC Jan13 20 Put $1.00

Cost basis $20.00 per share. Premiums collected: $1.00 per share 5% Return in 2 month

$10,000 would have generated $500.00

VirnetX Holding Corporation develops software and technology solutions for securing real-time communications over the Internet. The company s software and technology solutions include domain name registry and GABRIEL Connection Technology, which provide security platform for Internet-based applications, such as instant messaging, voice over Internet protocol, mobile services, streaming video, file transfer, and remote desktop. It also intends to provide a portfolio of licenses and services comprising VirnetX technology; GABRIEL Connection Technology software development kit, including object libraries, sample code, and testing and quality assurance tools, as well as documentation support services required by customers to implement the company s technology; domain name registrar service; technical support; and secure domain name master registry and connection services. The company serves original equipment manufacturers in the Internet protocol telephony, mobility, fixed-mobile convergence, and unified communications markets. VirnetX Holding Corporation was founded in 2005 and is headquartered in Zephyr Cove, Nevada.

VirnetX Holding Corp

308 Dorla Court

Suite 206

Zephyr Cove, NV 89448

Phone: 775-548-1785

Fax: 775-580-7527

Website: http://www.virnetx.com

ZNGA @ $2.45

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $14.00 per share. Premiums collected: $2.05 per share 14.64% Return in 11 months

$10,000 would have generated $1464.00

actual trades:

03/19/2012 Sell To Open ZNGA Apr12 16 Call $0.20

03/18/2012 Buy To Close EXPIRED ZNGA MAR12 15 CALL

02/21/2012 Sell To Open ZNGA Mar12 15 Call $0.40
02/17/2012 BuyZNGA – Option Assignment $14.00
02/17/2012 Buy To Close ZNGA Feb12 14 Put

02/06/2012Sell To Open ZNGA Feb12 14 Put$1.55

Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms. The company offers its online social games under the CityVille, Zynga Poker, FarmVille, CastleVille, FrontierVille, Mafia Wars, Word with Friends, Hidden Chronicles, Zynga Bingo, Scramble With Friends, Slingo, and Dream Heights names. Its games are available on various platforms, including Facebook and other social networks, as well as mobile platforms, such as Apple iOS and Google Android worldwide. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Zynga, Inc.

699 Eighth Street

San Francisco, CA 94103 Phone: 855-449-9642 Fax: 302-636-5454

Website: http://www.zynga.com

News:

http://allthingsd.com/20121221/the-first-signs-of-zyngas-online-gambling-efforts-go-live-in-the-u-k/

Quote of the Month:

“I violated the Noah rule: Predicting rain doesn’t count; building arks does.”

~ Warren Buffet

Happy New Year!

Until Next Time

Brad Lee

The Options Oracle

https://theoptionsoracle.com/

Ask The Oracle
webinar Sunday 8 pm estto
explain this newsletter, or other
questions you might have.
Here is the link
http://www.anymeeting.com/MoneyMedic1
There is no preregistration.
Summary:
sell to open CLWR March13 $3
call @ Market
Sell To Open ELN April13 $12
Call @ Market
Sell To Open FMCN April13 $27
Call @ Market
Sell To Open PAY July13 43 Call
@ market
Sell To Open QCOR April13 $35
Call @ Market
Sell To Open CLSN Feb 2013

$2 Put @ Market
Past performance click here: https://theoptionsoracle.com/past-performances/

Auto-trading is for you. Your account will

automatically do whatever I do.

You are still in control, you set the limits either a dollar amount or a percentage.

Go to:

https://theoptionsoracle.com/auto-trading/

Disclosure: These are my actual trades.
Your subscription fee may be 100%
TAX DEDUCTIBLE if used for
educational business/investment
purposes. Check with your Licensed
Professional adviser
Company News
Auto Trading is now active!
Don’t want to be bothered doing the
trades?
Auto-trading is for you. Your account will
automatically do whatever I do.
You are still in control, you set the limits
either a dollar amount or a percentage.
Go to the main site, the Auto-trade link
is on the site
https://theoptionsoracle.com/
We will be doing a webinar
Sunday 8 pm est to explain this
Here is the link
http://www.anymeeting.com/MoneyMedic1
Disclosure: These are my actual trades.
Your subscription fee may be 100%
TAX DEDUCTIBLE if used for
educational business/investment
purposes. Check with your Licensed
Professional adviser
Options involve risk and are not suitable for
all investors. Prior to trading options, you
must be approved for options trading and
read the Characteristics and Risks of
Standardized Options.
Copies of this document may also be
obtained from your broker, from any

exchange on which options are traded, by placing an order online, or by contacting the Options Clearing Corporation directly at 1 N. Wacker Dr., Suite 500, Chicago, IL 60606. (1-888-678-4667).

Brad Lee AKA “The Options Oracle” and “The Money Medic” is an individual investor who does not manage money for any financial institution. You are purchasing the list of stocks that he uses to select options contracts he feels will return him the highest, safest profits. Brad is not a broker, or financial adviser. He is a remarkable investor who has developed a successful strategy for himself, and is willing to share some of his magic with you. We urge you to paper trade these picks and learn how to develop a strategy that is appropriate for you. Thank You.

We make no recommendations on investment and we do not provide financial, tax or legal advice. Content and tools are provided for educational and informational purposes only.

Disclaimer

Trading or investment in stocks, futures & options, and commodity are subject to potential market risks. You can use our materials or recommendations for educational purposes, this is not intended as Trading or Investment advice. We are not financial advisers. We cannot provide any advice as to whether or not options or our trading ideas are suitable investments for your particular financial situation. We are in the business of publishing our trade ideas for market analysis only. We highly recommend that our subscribers review their trading allocation with a qualified registered financial adviser/planner.

Legal Disclaimer: we do not exist to render and do not give legal, tax, economic or investment advice and disclaims all liability for the actions or inaction taken or not as a result of communications from or to its members, officers, directors, employees and contractors. Each individual should consult his/her own counsel, accountant and other advisors as to legal, tax, economic, investment and related matters concerning any type of investments.

This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is confidential and privileged. If you receive this email in error, please advise us by return email immediately.

Please also disregard the contents of the email, delete it and destroy any copies immediately.